简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
News
Year
2021
2022
2023
2024
2025
2026
Month
1
2
3
4
5
6
7
8
9
10
11
12
Boan Biotech Announces 2026 Interim Results
2026.08.28
IND Application for Boan Biotech’s TL1A/IL-23 Bispecific Antibody BA2201 Accepted in China
2026.08.27
Boan Biotech Announces Successful Completion of Phase Ia Clinical Trial of BA1302 (CD228-Directed ADC) in China
2026.08.17
06
2026-08
Boan Biotech Submits BLA for Aflibercept Intravitreous Injection in Brazil
08
2026-07
China’s CDE Accepts IND Application for Boan Biotech’s BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)
03
2026-07
Boan Biotech Receives CDE Clearance for Phase Ⅱ Clinical Trial of BA1106 in Combination with BA1104 for NSCLC
04
2026-06
Boan Biotech Out-licenses Its Dulaglutide Injection in the U.S.
01
2026-06
Boan Biotech Presents Updated Phase I Clinical Data for BA1301 (Anti-CLDN18.2 ADC) at the 2026 ASCO Annual Meeting
29
2026-05
Boan Biotech Submits a Biologics License Application for Two Denosumab Biosimilars in the U.S.
26
2026-05
Boan Biotech’s Boluojia® Newly Approved in China for Treating Bone Metastases from Solid Tumors and Multiple Myeloma
1
2
3
4
5
Follow me
鲁公网安备37069102000284